ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0272

Risk Factors for Severe Outcome in Susac Syndrome: A National Cohort Study

Marion Peyre1, Arthur Mageau1, Marie-cecile Henry Feugeas2, Serge Doan2, Caroline Halimi2, Isabelle Klein3, Tiphaine Goulenok2, Chrystelle Francois2, Marie-Paule Chauveheid2, Thomas Papo1 and Karim Sacre1, 1Université Paris Cité, Paris, France, 2Assistance Publique Hopitaux de Paris, Paris, France, 3Clinique Alleray-Labrouste, Paris, France

Meeting: ACR Convergence 2023

Keywords: Miscellaneous Rheumatic and Inflammatory Diseases, neurology, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0252–0282) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Susac syndrome (SuS) is a rare vasculitis affecting the brain, retina and inner ear in young women. Nonreversible hearing loss is the main long-term damage of SuS and requires hearing aids in more than 50% of patients. There are no known predictive factors for poor outcomes in SuS. We aimed to identify risk factors for severe hearing loss in Susac Syndrome.

Methods: SuS patients have been included in the prospective national cohort study (CarESS study) involving 20 different centres in France. CarESS study is an ongoing cohort study that started in December 2011 including all consecutive patients with SuS referred to the French reference center (Department of Internal Medicine, Bichat Claude Bernard Hospital, Paris). SuS was defined either by the triad of encephalopathy with corpus callosum ischemic lesions on brain MRI, cochleo-vestibular damage including sensorineural hearing loss and multiple occlusions of retinal central artery branches and/or retinal vasculitis on retinal fluorescein angiography. Collected data included age, gender, physical examination, fundoscopy, retinal angiography, visual acuity, visual field, audiogram, cerebrospinal fluid, brain MRI and treatment received. The CarESS study was designed with a follow-up at 1, 3 months, 6 months, 12 months after diagnosis and then annually for 5 years and/or in the event of a relapse. Fundoscopy, audiogram, and brain MRI were systematically scheduled at each time-point. The primary outcome was the occurrence of severe hearing loss (HL) at last follow-up. Severe HL was defined as the loss of 70dB in at least one ear on audiogram or the need for hearing aids.

Results: Overall, 36 SuS patients were analyzed for the primary outcome. Twenty-four patients (66.7%) were women and the median age at diagnosis was 37.5 [24.5-42.5] years. The triad was complete in 29 (80.6%) patients at disease onset. Thirty-three patients (91.7%) had cochlea-vestibular involvement at SuS diagnosis including tinnitus (n=16), dizziness (n=15), ataxia (n=7) and HL >20dB in at least one ear (n=25). At diagnosis, thirty-two (88.9%), 11 (30.6%) and 7 (19.4%) patients have received steroids, intravenous immunoglobulin and/or immunosuppressive drugs (IS), respectively. After a median follow up of 50.7 [24-73.4] months, 20 patients (58.3%) experienced severe HL that occurred a median time of 2.1 [0.3 – 13.6] months after diagnosis. Multivariable logistic regression model showed that odds of severe HL were lower in patients who received IS drugs at diagnosis (OR 0.13 95% CI [0.01-0.93], p=0.041).

Conclusion: Severe hearing loss is frequent in patients with Susac syndrome and associated with the absence of immunosuppressive drugs given at diagnosis. Our findings support the systematic use of immunosuppressive drugs in Susac syndrome to prevent poor outcome, which should be tested in a multicenter prospective randomized trial.


Disclosures: M. Peyre: None; A. Mageau: None; M. Henry Feugeas: None; S. Doan: None; C. Halimi: None; I. Klein: None; T. Goulenok: None; C. Francois: None; M. Chauveheid: None; T. Papo: None; K. Sacre: None.

To cite this abstract in AMA style:

Peyre M, Mageau A, Henry Feugeas M, Doan S, Halimi C, Klein I, Goulenok T, Francois C, Chauveheid M, Papo T, Sacre K. Risk Factors for Severe Outcome in Susac Syndrome: A National Cohort Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/risk-factors-for-severe-outcome-in-susac-syndrome-a-national-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-for-severe-outcome-in-susac-syndrome-a-national-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology